{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:30:49Z","timestamp":1789421449697,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.leukres.2015.11.002","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T05:02:13Z","timestamp":1447131733000},"page":"68-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L\/K mutations"],"prefix":"10.1016","volume":"40","author":[{"given":"Masahiro","family":"Okabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tajika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Gomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyoshi","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihito","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koiti","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2015.11.002_bib0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2015.11.002_bib0010","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"434 (7037)","key":"10.1016\/j.leukres.2015.11.002_bib0015","first-page":"1144","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"200","author":"James","year":"2015","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.leukres.2015.11.002_bib0020","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.leukres.2015.11.002_bib0025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"9464","key":"10.1016\/j.leukres.2015.11.002_bib0030","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.leukres.2015.11.002_bib0035","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4161\/cc.6.5.3919","article-title":"Oncogenes in myeloproliferative disorders","volume":"6","author":"Tefferi","year":"2007","journal-title":"Cell Cycle"},{"issue":"17","key":"10.1016\/j.leukres.2015.11.002_bib0040","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2015.11.002_bib0045","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.leukres.2015.11.002_bib0050","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2015.11.002_bib0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.leukres.2015.11.002_bib0060","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Lee","year":"2006","journal-title":"PLoS Med."},{"issue":"3","key":"10.1016\/j.leukres.2015.11.002_bib0065","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2015.11.002_bib0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.11.002_bib0075","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/asheducation-2006.1.240","article-title":"Classsification diagnosis and management of myeloproliferative disorders in the JAK2V617F era","volume":"2006","author":"Tefferi","year":"2006","journal-title":"Hematol. Am. Soc. Hematol. Educ. Prog."},{"issue":"10","key":"10.1016\/j.leukres.2015.11.002_bib0080","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/leu.2009.110","article-title":"The \u2018GGCC\u2019 haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera","volume":"23","author":"Olcaydu","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2015.11.002_bib0085","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/leu.2010.1","article-title":"MPL mutation effect on JAK2 46\/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms","volume":"24","author":"Patnaik","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2015.11.002_bib0090","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-2141.2005.05683.x","article-title":"The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera","volume":"130","author":"Cario","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2015.11.002_bib0095","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.leukres.2015.11.002_bib0100","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2008-03-143602","article-title":"Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden","volume":"112","author":"Landgren","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2015.11.002_bib0105","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.leukres.2015.11.002_bib0110","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.leukres.2015.11.002_bib0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","article-title":"Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia","volume":"93","author":"Antonioli","year":"2008","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.leukres.2015.11.002_bib0120","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2015.11.002_bib0125","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2015.11.002_bib0130","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2015.11.002_bib0135","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2015.11.002_bib0140","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/sj.leu.2404724","article-title":"Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera","volume":"21","author":"Tefferi","year":"2007","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2015.11.002_bib0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1532\/IJH97.06009","article-title":"Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group","volume":"83","author":"Dan","year":"2006","journal-title":"Int. J. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2015.11.002_bib0150","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"Elliott","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"25","key":"10.1016\/j.leukres.2015.11.002_bib0155","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.leukres.2015.11.002_bib0160","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2015.11.002_bib0165","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.leukres.2007.12.019","article-title":"Fully automated and super-rapid system for the detection of JAK2V617F mutation","volume":"32","author":"Tanaka","year":"2008","journal-title":"Leuk. Res."},{"issue":"19","key":"10.1016\/j.leukres.2015.11.002_bib0170","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","article-title":"In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology","volume":"124","author":"Barbui","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2015.11.002_bib0175","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.leukres.2015.11.002_bib0180","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2015.11.002_bib0185","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2015.11.002_bib0190","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.leukres.2015.11.002_bib0195","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2015.11.002_bib0200","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ajh.21183","article-title":"Essential thrombocythemia polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy","volume":"83","author":"Tefferi","year":"2008","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2015.11.002_bib0205","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2015.11.002_bib0210","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict\u3000survival in 867 World Health Organization-defined essential thrombocythemia\u3000at diagnosis: a study by the International Working Group on\u3000Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2015.11.002_bib0215","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1182\/blood-2006-12-038968","article-title":"How treat patients with polycythemia vera","volume":"109","author":"Finazzi","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2015.11.002_bib0220","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.leukres.2015.11.002_bib0225","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2015.11.002_bib0230","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.leukres.2015.11.002_bib0235","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2015.11.002_bib0240","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615305403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615305403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T07:28:32Z","timestamp":1567322912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212615305403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":48,"alternative-id":["S0145212615305403"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2015.11.002","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L\/K mutations","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2015.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}